Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications

被引:8
|
作者
Mackey, John
Gelmon, Karen
机构
[1] Cross Canc Inst, Alberta Canc Board, Edmonton, AB T6G 1Z2, Canada
[2] Univ Alberta, Dept Med & Expt Oncol, Edmonton, AB, Canada
[3] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
anastrozole; aromatase inhibitors; arthralgia; breast cancer; exemestane; fractures;
D O I
10.1097/01.cco.0000266466.62197.5c
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aromatase inhibitors, which offers profound suppression of estrogen synthesise, have been introduced as long-term adjuvant therapeutic agents for postmenopausal women with breast cancer. Compared with tamoxifen treatment, which has long been the standard of care in anti-estrogen therapy, third-generation aromatase offer superior efficacy with regard to disease-free survival rates. The aromatase inhibitors anastrozole, letrozole and exemestane have a different toxicity profile from tamoxifen and are relatively free of some of the side effects associated with tamoxifen, such as deep vein thrombosis and uterine malignancies. They can, however, cause bone and joint pain (arthralgia), as well as the loss of bone mineral density and an increased incidence of fractures. These events appear to arise as class effects for the aromatase inhibitors, as they occur with all members of this structurally and mechanistically diverse group of drugs. Here we summarize the latest data on the efficacy of aromatase inhibitors and their effects on the risk of arthralgia and other musculoskeletal complications; notably from five ongoing clinical trials comparing aromatase inhibitors with tamoxifen or placebo.
引用
收藏
页码:S9 / S18
页数:10
相关论文
共 50 条
  • [21] Adherence challenges in breast cancer: Evaluating tamoxifen and aromatase inhibitors in adjuvant hormone therapy
    Camejo, N.
    Amarillo, D.
    Castillo, C.
    Argenzio, L.
    Santana, D.
    Herrera, G.
    Cabrera, L.
    Guerrina, M.
    Dorner, C.
    Krygier, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 35 - 36
  • [22] A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
    Petit, Thierry
    Dufour, Patrick
    Tannock, Ian
    ENDOCRINE-RELATED CANCER, 2011, 18 (03) : R79 - R89
  • [23] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Holm Eggemann
    Atanas Ignatov
    Bobbie J. Smith
    Udo Altmann
    Gunter von Minckwitz
    Freidrich W. Röhl
    Mark Jahn
    Serban-Dan Costa
    Breast Cancer Research and Treatment, 2013, 137 : 465 - 470
  • [24] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
    Eggemann, Holm
    Ignatov, Atanas
    Smith, Bobbie J.
    Altmann, Udo
    von Minckwitz, Gunter
    Roehl, Freidrich W.
    Jahn, Mark
    Costa, Serban-Dan
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 465 - 470
  • [25] A study of adverse vascular effects of adjuvant therapy with aromatase inhibitors in women with breast cancer
    Lindman, H.
    Dahlberg, L.
    Larsson, M.
    Naessen, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer
    Nabholtz J.-M.
    Mouret-Reynier M.-A.
    Durando X.
    van Praag I.
    Nayl B.
    Ferriere J.-P.
    Chollet P.
    Indian Journal of Surgical Oncology, 2010, 1 (1) : 19 - 26
  • [27] Aromatase inhibitors and inactivators for breast cancer therapy
    Lonning, PE
    DRUGS & AGING, 2002, 19 (04) : 277 - 298
  • [28] Aromatase inhibitors for therapy of advanced breast cancer
    Ingle, JN
    Suman, VJ
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 95 (1-5): : 113 - 119
  • [29] Aromatase inhibitors and inactivators for breast cancer therapy
    Lønning P.E.
    Drugs & Aging, 2002, 19 (4) : 277 - 298
  • [30] Drug therapy: Aromatase inhibitors in breast cancer
    Smith, IE
    Dowsett, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24): : 2431 - 2442